Amgen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Amgen Inc. $AMGN Position Boosted by Elevation Point Wealth Partners ...

AI-generated analysis

📈 Elevation Point Wealth Partners LLC boosted its Amgen stake by 91.9% in Q1, adding 10,271 shares to a total holding of 21,443 shares.

💰 The company reported $5.15 EPS for the quarter, beating analyst estimates of $4.77 by $0.38.

📊 Revenue reached $8.62 billion, representing a 5.8% year-over-year increase.

🎯 Amgen provided FY 2026 guidance with EPS expectations ranging from $21.70 to $23.10.

📉 Wall Street Zen downgraded the stock from 'buy' to 'hold', contributing to a consensus 'Hold' rating.

💸 SVP Nancy A. Grygiel sold 1,237 shares for approximately $400,454 in a transaction on May 4th.

🏢 Institutional ownership stands at 76.5% of the company's total outstanding stock.

📉 Daiwa Securities Group lowered its price target to $390 while maintaining an 'outperform' rating.

Bullish Signals
  • Amgen beat quarterly earnings estimates with EPS of $5.15 versus a consensus of $4.77, demonstrating strong profitability.
  • Revenue grew by 5.8% year-over-year to reach $8.62 billion, indicating solid top-line growth.
  • The company achieved a high net margin of 20.96% and an impressive return on equity of 137.41%.
  • Major institutional investor Elevation Point Wealth Partners increased its position by 91.9%, signaling confidence in the stock.
  • Daiwa Securities Group maintains an 'outperform' rating despite lowering the price target, suggesting continued long-term optimism.
Risk Factors
  • Wall Street Zen downgraded the stock from a 'buy' to a 'hold' rating on June 27th.
  • Guggenheim lowered its price target from $351.00 to $340.00 and assigned a 'neutral' rating.
  • SVP Nancy A. Grygiel sold 1,237 shares of company stock, reducing her personal ownership by 15%.
  • The consensus analyst price target of $355.50 is below the recent trading price mentioned in insider transactions ($323.73 average sale price), though this reflects a discount rather than a direct negative signal.
Full Analysis
Elevation Point Wealth Partners LLC significantly increased its position in Amgen Inc. (NASDAQ:AMGN) by 91.9% in the first quarter, purchasing an additional 10,271 shares to hold a total of 21,443 shares valued at $7.545 million. Other institutional investors also adjusted their stakes, with Brighton Jones LLC increasing holdings by 23.5%, Schnieders Capital Management by 29.3%, and Ieq Capital by 5.1%. Collectively, institutional investors own 76.5% of the company's outstanding stock. Amgen recently reported strong financial results for the quarter ended April 30th, posting $5.15 in earnings per share which beat analyst consensus estimates of $4.77 by $0.38. The company generated revenue of $8.62 billion, a 5.8% increase year-over-year, with a net margin of 20.96% and a return on equity of 137.41%. Management has provided full-year 2026 guidance for EPS between $21.70 and $23.10, while Wall Street analysts currently forecast an average EPS of $22.39. Analyst sentiment remains mixed with a consensus rating of 'Hold' and an average price target of $355.50. Recent actions include Daiwa Securities Group lowering its target price to $390 while maintaining an 'outperform' rating, whereas Wall Street Zen downgraded the stock from 'buy' to 'hold'. Insider trading activity saw SVP Nancy A. Grygiel sell 1,237 shares at an average price of $323.73, reducing her personal ownership by 15%.